An article from the 'Märkische Allgemeine' reports on companies from Brandenburg, which develop therapeutics and diagnostics for COVID-19.
Hennigsdorf, August 2021 - The medical technology company Pentracor GmbH, based in Hennigsdorf near Berlin, publishes an interview with CEO Dr. Ahmed Sheriff.
The innovative and cutting-edge therapy CRP apheresis convinces.
Avoiding serious tissue damage in myocardial infarction and preserving cardiac output. A clinical study on CRP apheresis after myocardial infarction showed significantly positive results. Other cases in clinical practice support these results. Similarly, 9 Covid-19 patients - one before and the others in intensive care - have recovered. The majority were already on artificial ventilation. Unfortunately, about 50 percent of these patients die under normal conditions when treated according to guidelines.
Pentracor recently joined the BVMed business association, which represents the interests of the German medtech industry and, in particular, medtech SMEs. BVMed represents around 220 industrial and commercial companies in the medical technology sector. Among others, the world's 20 largest medical device manufacturers in the consumer goods sector are organized in BVMed.
Recently a new case report has been published in Frontiers in Immunology about the first COVID-19 patient at the onset of a severe COVID-19 course. Small heads-up: it turned out amazingly well!
Another case report has been published on the successful treatment of a young, ventilated COVID-19 patient in Immenstadt. One very effective CRP apheresis was sufficient. Afterwards, the patient's clinical parameters were back to normal.
Hennigsdorf, July 28, 2021 - The medical technology company Pentracor GmbH, based in Hennigsdorf near Berlin has published its 2020 annual financial statements. The financial year was characterized by the roll-out of the PentraSorb® CRP medical product developed and certified by the company, as well as the initiation and execution of clinical studies to increase acceptance for CRP apheresis in the treatment of diseases associated with acute inflammation such as myocardial infarction.
In the 3rd issue of "Intensiv-News" 2021, the most recent publications on CRP apheresis were summarized and evaluated with a focus on the recently published CAMI-1 study.
Twelve companies have been nominated by the main jury for the "Zukunftspreis Brandenburg" 2021. Six prize winners and one company as a special prize winner will be awarded Brandenburg's most important business prize in the final on November 12 at the Airport Center Berlin Schönefeld. Pentracor GmbH, based in Hennigsdorf, is among the nominees. "We are very honored by the nomination," said Pentracor CEO Dr. Ahmed Sheriff.
ntv has broadcast an interview with Dr. Ahmed Sheriff about CRP apheresis for COVID-19 patients. Among other things, they talk about the lack of funding for medical devices in the Corona Pandemic.